Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets

Genes Chromosomes and Cancer

Volumn 22, Issue 2, 1998, Pages 157-163

  Walker, Graeme J ^a,b   Flores, José F ^a   Glendening, J Michael ^a   Lin, Amy ^a   Markl, Isabel D C ^a   Fountain, Jane W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DNA FLANKING REGION; ENZYME INHIBITION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE DELETION; HUMANS; MELANOMA; MUTATION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0031980540     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N     Document Type: Article

References (45)

1. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC (1996) Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of human fibroblasts. Proc Natl Acad Sci USA 93:13742-13747.
2. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J (1996) The p16-cyclin D/CDK4-pRB pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483.
3. Brenner AJ, Aldaz CM (1995) Chromosome 9p allele loss in breast cancer and evidence of p16 inactivation in immortal breast epithelium cells. Cancer Res 55:2893-2895.
4. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 11:210-212.
5. Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK (1997) CDKN2A is altered in most melanoma cell lines. Cancer Res 57:4868-4875.
6. Dracopoli NC, Fountain JW (1996) CDKN2A mutations in melanoma. Cancer Surv 26:115-131.
7. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, Seddon J, Tarbell N, Boice JD, Jr (1993) Mortality from second tumors amoung long-term survivors of retionoblastoma. J Natl Cancer Inst 85:1121-1128.
8. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56:5023-5032.
9. Foulkes WD, Flanders TY, Pollock PM, Hayward NK (1997) The CDKN2A (p16) gene and human cancer. Mol Med 3:5-20.
10. Fountain JW, Karayiorgou M, Taruscio D, Graw SL, Buckler AJ, Ward DC, Dracopoli NC, Housman DE (1992a) Genetic and physical map of the interferon region on 9p. Genomics 14:105-112.
11. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE, Dracopoli NC (1992b) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89:10557-10561.
12. INK4a gene) during tumor progression in a sporadic melanoma patient. Cancer Res 55:5531-5535.
13. Gonzalgo ML, Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW (1997) Low frequency of p16/CDKN2A methylation in sporadic melanoma: Comparative approaches for methylation analysis of primary tumors. Cancer Res 57:5336-5347.
14. Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castenada V, Lianes P, Latres E, Skolnick M, Cordon-Cardo C, Kamb A (1995) Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways in tumor progression. Am J Pathol 146:1199-1206.
15. INK4B is a potential effector of TGF-&bgr;-induced cell cycle arrest. Nature 371:257-261.
16. CDKN2 expression and its implication for cell immortalization and senescence. Mol Cell Biol 16:859-967.
17. Healy E, Sikkink S, Rees JL (1996) Infrequent mutation of CDKN2A in sporadic melanoma. J Invest Dermatol 107:318-321.
18. INK4) mutations in sporadic melanoma in vivo. J Invest Dermatol 108:950.
19. Kamb A, Gruis N, Weaver-Feldhaus J, Lui Q, Haeshman K, Tavtigian SV, Stocken E, Day RS III, Johnson BE, Skolnick M (1994) A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264:436-440.
20. INK4b in undifferentiated mouse skin tumors. Cancer Res 55:5168-5172.
21. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allanunis-Turner MJ, Skolnick MH, Fujimura FJ, Kamb A (1995) CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067.
22. Loughran O, Edington KG, Berry IJ, Clark LJ, Parkinson EK (1994) Loss of heterozygosity on chromosome 9p21 is associated with immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Res 54:5045-5049.
23. Luca M, Xie S, Gutman M, Huang S, Bar-Eli M (1995) Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene 11:1399-1402.
24. INK4a/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 55:4818-4823.
25. Mælandsmo GM, Flørenes VA, Hovig E, Øyjord T, Engebraaten O, Holm R, Børresen A-L, Fodstad Ø (1996) Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 73:909-916.
26. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995) A novel p16INK4A transcript. Cancer Res 55:2995-2997.
27. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1:686-692.
28. Nobori T, Muira K, Wu D, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
29. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Sing AD, Shields JA, Groce CM, Huebner K (1994) Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 54:5269-5272.
30. Ohta M, Berd D, Shimuzu M, Nagai H, Cotticelli M-G, Mastrangelo M, Shields JA, Shields CL, Croce CM, Huebner K (1996) Deletion mapping of chromosome region 9p21-22 surrounding the CDKN2 locus in melanoma. Int J Cancer 65:762-767.
31. Piccinin S, Doglioni C, Maestro R, Vukosavljevic T, Gasparotto D, D'Orazi C, Boiocchi M (1997) p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 74:26-30.
32. Platz A, Ringborg U, Lagerlof E, Sevigny P, Iganas M (1996) Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer 73:344-348.
33. Pollock PM, Yu F, Qiu L, Parson P, Hayward NK (1995) Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene 11:663-668.
34. Puig S, Ruiz A, Lazaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro JM, Estivill X (1995) Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside of the p16 (CDKN2) gene. Am J Hum Genet 57:395-402.
35. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995a) Alternative reading frames of the INKa tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
36. Quelle DE, Ashmun RE, Hannon GJ, Rehberger PA, Trono D, Richter KH, Walker C, Beach D, Sherr CJ, Serrano M (1995b) Cloning and characterization of murine p16Ink4a and p15Ink4b genes. Oncogene 11:635-645.
37. Sanders BM, May M, Draper GJ, Roberts EM (1989) Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer 60:358-365.
38. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
39. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602.
40. Stone S, Jiang P, Dayanath P, Tavtigian SV, Parry D, Peters G, Kamb A (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988-2994.
41. INK4a. Cancer Res 54:5816-5820.
42. Tsao H, Benoit E, Sober AJ, Thiele C, Haluska, FG (1998) Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 58:109-113.
43. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323-330.
44. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1285.
45. INK4a binding domain of CDK4 in familial melanoma. Nature Genet 12:97-99.